Caribou Biosciences

Company snapshot

Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 19 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Caribou Biosciences. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Caribou Biosciences.

1. Jun 5, 2026 Clinical update

   CB-012 — Phase 1

2. Jun 5, 2026 Clinical update

   CB-011 — Phase 1

3. Jun 5, 2026 Clinical update

   CB-010 — Phase 1

4. May 23, 2026 Clinical update

   CB-010 — Phase 1

5. Mar 26, 2024 Patent grant

   Modified cascade ribonucleoproteins and uses thereof

View all clinical trial activity →

• What is Caribou Biosciences?

  Caribou Biosciences is a biotech organization headquartered in Berkeley, USA. It trades on NYSE under ticker CRBU. Primary therapeutic focus areas include Lymphoma, Non-Hodgkin, Systemic Lupus Erythematosus, Relapsed/Refractory Multiple Myeloma, Acute Myeloid Leukemia, in Relapse

• Is Caribou Biosciences publicly traded?

  Yes. Caribou Biosciences is listed with ticker CRBU on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Caribou Biosciences develop or market?

  We link 2 drug profile(s) where Caribou Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/caribou-biosciences#company-drugs.

• What are the latest developments for Caribou Biosciences?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Caribou Biosciences focus on?

  Caribou Biosciences focuses on Lymphoma, Non-Hodgkin, Systemic Lupus Erythematosus, Relapsed/Refractory Multiple Myeloma based on our analysis of their pipeline programs and drug development activities.